Jin, Ran http://orcid.org/0000-0002-0245-9187
Kruppert, Silvia
Scholz, Florian
Bardoulat, Isabelle
Karzazi, Khalil
Morand, Francois
Kricorian, Greg
Collier, David
Kay, Jonathan
Funding for this research was provided by:
Amgen
Article History
Received: 2 November 2023
Accepted: 31 January 2024
First Online: 4 March 2024
Declarations
:
: Ran Jin and Greg Kricorian are employees and stockholders of Amgen. David Collier is a stockholder and former employee of Amgen. Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, and Francois Morand are employees of IQVIA Real World Solutions. Jonathan Kay has received research grants (paid to UMass Chan Medical School) from Aker BioMarine AS, Biogen, and Galapagos NV and is a consultant to Alvotech Swiss AG, Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., Fresenius Kabi, Novartis Pharmaceuticals Corp., Organon, Pfizer Inc., Samsung Bioepis, Teijin Pharma Ltd., Viatris Inc., and UCB Inc.
: This retrospective cohort analysis used fully de-identified IQVIA Longitudinal Prescription Data databases and therefore does not require patient consent for information on treatment histories or approval from an institutional review board or ethics committee. Consent from participants for publication is not applicable since no patient identifying information is included.